Ministry/Department Ministry of Railways Dr. Babasaheb Ambedekar Memorial Hospital, Central Railway Dr Ambedekar Road, Byculla East MUMBAI Attn: Md/Byculla-Medical/Central Rly. Description: Tenders are invited for 14501- Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved,
In response to the Surgeon General's call to make naloxone widely available it was announced today at NatCon18, the annual conference of National Council for Behavioral Health, that pharmaceutical companies, Adapt Pharma and Kaleo, are donating doses of naloxone, a potentially lifesaving drug that can help reverse opioid overdoses, to the National
Office Address: Department of the Army; Army Contracting Command; ACC- APG Natick; 10 General Green AvenueBuilding 1 Natick MA 01760-5011. Description: Department of the Army. DynPort Vaccine Company LLC, a General Dynamics Information Technology Company, a biopharmaceutical company in Frederick, Maryland, is issuing this Request for Information to
Office Address: Department of the Army; U.S. Army Medical Command; REGIONAL HEALTH CONTRACT OFF CENTRAL; ATTN: MCAA GP L31 9 V2539 GARDEN AVENUE JBSA FT SAM HOUSTON TX 78234-0000. Contact: Timothy T. Hoerz, Phone 2542856747, Email firstname.lastname@example.org. Description: Department of the Army.
On March 28, 2018, pSivida Corp. acquired specialty biopharmaceutical company Icon Bioscience Inc. pSivida Corp. rebranded and changed its name to EyePoint Pharmaceuticals Inc., with ticker EYPT, effective April 2, 2018. DEXYCU, a dropless, long-acting therapeutic, which was approved by the FDA for the treatment of inflammation in post catara
Findings from R.P. Rao and Colleagues Provides New Insights into Food Chemistry. By a News Reporter-Staff News Editor at Food Weekly News Current study results on Chemistry- Food Chemistry have been published. According to news reporting originating in Bangalore, India, by VerticalNews journalists, research stated, "A nutritional supplement FFD-0
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that five abstracts were accepted at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting in Honolulu, Hawaii, April 29 May 3,
Albany, NY 04/25/2018 Drug rescue is also termed as rescue medicines. These are given only when needed or in emergency cases. Drug which is given to counter or block the effect of other medicines are called as rescue medicines.
Albany, NY 04/26/2018 A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and mo
Minister Heather Humphreys T.D. and IDA Ireland today congratulated leading pharmaceutical outsourcing services provider PCI Pharma Services on the launch of its new contained packaging facility for the primary and secondary packaging of highly potent products at its newly acquired site in Drogheda, Co. Louth. The new facility will lead to the crea
STOCKHOLM, April 26st, 2018- On May 8th 2018, at 08:00 am, Moberg Pharma AB will present its interim report for January- March 2018. The teleconference will be hosted by Moberg Pharmas's CEO Peter Wolpert and CFO Anna Ljung. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB is a rapidly growing Swedish pharmaceutical company with OTC sales
New Gene Therapy Data Have Been Reported by Investigators at Loughborough University of Technology. Funders for this research include Engineering and Physical Sciences Research Council, Loughborough University, York University. Our news journalists obtained a quote from the research from the Loughborough University of Technology, "This confers a...
By a News Reporter-Staff News Editor at Gene Therapy Weekly Pfizer Inc. has initiated a Phase 1 b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy. "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfiz
CPH Dean Dr Mohammad Diab and Qatar Pharma CEO Dr Ahmed Mohammad Al Sulaiti signing the MoU. The MoU was signed by CPH Dean, Dr Mohammad Diab and Qatar Pharma CEO, Dr Ahmed Mohammad Al Sulaiti, in the presence of QU President, Dr Hassan Al Derham and officials from both institutions. Dr Ahmed Mohammad Al Sulaiti said: It is our pleasure today to
Doris O. Matsui, D- California, issued the following opening remarks at the House Energy and Commerce subcommittee on Health markup on opioid legislation and the Animal Drug and Animal Generic Drug User Fee Amendments:. "Our Committee has a daunting, yet absolutely essential, task before us today: to make policy changes that address the opioid epi
Albany, NY 04/25/2018 The packaging industry is witnessing an impressive growth over the past few years and various new packaging solutions are launched in order to cater increasing need of customers. Packaging of medicines is a complicated process, due to its complex molecular structure of chemicals used in origination of drugs. So, there is
SOUTH SAN FRANCISCO- Roche Holding AG reported that its group sales for the first-quarter increased 6% at constant exchange rates and 5% in Swiss francs. Roche CEO Severin Schwan said, "We have started the year with strong sales growth in both our Pharmaceuticals and Diagnostics Divisions. It continued its strong growth in the US and was launched i
Saniona, a leading biotech company in the field of ion channels, today announced that it has obtained approval to initiate the second part of its Phase 2 a trial for Tesomet in adolescents with Prader-Willi syndrome. By pursuing an orphan indication such as Prader-Willi syndrome, we may develop and commercialize our own product in the U.S. and Euro
The European Medicines Agency issued the following news release:. The European Network of Paediatric Research at the European Medicines Agency will hold its tenth annual workshop on 7-8 June 2018 at the European Medicines Agency. It counts forty six member networks from Europe, Canada, Japan and the United States.
This was stated by Hakim Rizwan Hafeez Malik, former president of National Council for Tibb while he, as a chief guest, was addressing the concluding session of 2- day symposium, organized by Faculty of Eastern Medicine, Hamdard University on theme:' Challenges and opportunities for Unani Medicine in Contemporary World', at Bait al-Hikmah auditoriu
Albany, NY 04/25/2018 Vitamin deficiency, also called as hypovitaminosis, is primarily caused by malnutrition. The rate of undernourishment is high in undeveloped and developing countries such as Africa, Vienna and some parts of South-East Asia. Vitamin deficiency can lead to various diseases such as vitamin D deficiency causes rickets, vitam
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome. Glepaglutide is in development as a new treatment option for patients with short bowel syndrome The pivotal phase 3 trial is on track for initiation in Q3 2018 Copenhagen, Denmark, April 26, 2018- Zealand Pharma today announced receipt of the End-
22nd Century Group, Inc., a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company is committed to working collaboratively with the U.S. Food and Drug Administration on the FDA s planned nicotine reduction mandate despite the fact that, last week, regulations.gov published re
AbbVie, a research-based global biopharmaceutical company, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 inhibitor, being evaluated for treatment of patients with moderate to severe plaque psoriasis. "The risankizumab submission represe
AbbVie, a research-based global biopharmaceutical company, today announced positive results from the ongoing Phase 2 b/3 SELECT-SUNRISE clinical trial, showing that at 12 weeks, all doses of upadacitinib met the study's primary endpoint of ACR20 a versus placebo. 1 Certain key efficacy endpoints were also achieved versus placebo. 1 The study, con